Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-11-06 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药第二期员工持股计划（草案）
Capital/Financing Update Classification · 95% confidence The document is titled "国邦医药集团股份有限公司 第二期员工持股计划（草案）" which translates to "Guobang Pharmaceutical Group Co., Ltd. Second Employee Stock Ownership Plan (Draft)". It is a detailed plan document describing the employee stock ownership plan, including its purpose, principles, participants, funding sources, stock sources, stock quantities, pricing, management structure, rights and obligations of participants, risk warnings, and other operational details. The document is lengthy (15,000 characters) and contains substantive content about the employee stock ownership plan rather than just an announcement or summary. It is not an annual report, earnings release, or regulatory filing. It is a detailed plan document related to employee stock ownership, which is a form of capital/financing update related to company fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-11-06 Chinese
国邦医药第三届董事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the first meeting of the third board of directors of Guobang Pharmaceutical Group Co., Ltd. It details the election and appointment of board members and senior management positions, as well as approval of employee stock ownership plans and authorization for related matters. The document does not contain financial statements or detailed financial analysis but focuses on board and management changes and governance matters. It also references other announcements for further details. Given the content focuses on board elections, appointments, and governance structure, the appropriate classification is Board/Management Information (MANG). The document length is 3776 characters, which is consistent with an announcement rather than a full report.
2025-11-06 Chinese
国邦医药2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2025 first extraordinary shareholders meeting of Guobang Pharmaceutical Group Co., Ltd. It details the meeting date, location, attendance, voting results on various proposals including board elections and amendments to company rules. It includes legal opinions confirming the legality and validity of the meeting and resolutions. The document is a formal announcement of the voting results from a shareholders meeting, not the meeting materials or the meeting itself. It is not a full annual or interim report, nor a management or earnings report. The content fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 4,135 characters, consistent with a detailed voting results announcement rather than a full report.
2025-11-06 Chinese
国邦医药2025年第二次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2025 Second Extraordinary General Meeting of Shareholders" of Guobang Pharmaceutical Group Co., Ltd. It includes the meeting agenda, meeting instructions, and detailed proposals for shareholder approval, specifically regarding the company's second employee stock ownership plan. The content is focused on the meeting itself, including procedural details, voting instructions, and the proposals to be discussed and voted on. There is no financial data or report content such as financial statements or management discussion and analysis. The document is a set of materials prepared for a shareholders' meeting, which aligns with the definition of AGM Information (AGM-R), as it is presentation and materials shared during a general meeting. The document length is 4093 characters, which is consistent with meeting materials rather than a full report. Therefore, the appropriate classification is AGM Information (AGM-R).
2025-11-06 Chinese
国邦医药关于召开2025年第二次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about the convening of the 2025 second extraordinary general meeting of shareholders (临时股东会) for Guobang Pharmaceutical Group Co., Ltd. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or results but is an announcement related to a shareholder meeting. The document length is 2916 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document is best classified as a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-11-06 Chinese
国邦医药薪酬与考核委员会关于公司第二期员工持股计划相关事项的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the company's second employee stock ownership plan. It references compliance with company law, securities law, and regulatory guidelines related to employee stock plans. The content focuses on the legality, procedures, and governance aspects of the employee stock plan rather than financial results or capital changes. The document is relatively short (919 characters) and does not contain financial statements or data. It is a governance-related committee opinion on remuneration and employee stock plans, which aligns best with Remuneration Information filings. Therefore, the appropriate classification is 'DEF 14A' (Remuneration Information).
2025-11-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.